Evidence map›Paper›PMID 35452083›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.

Alexander E Perl, Paresh Vyas

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alexander E PerlDivision of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Paresh VyasMRC Molecular Haematology Unit, Oxford Biomedical Research Center Hematology Theme, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-3931-0914
MRC Weatherall Institute of Molecular Medicine · GBUniversity of Pennsylvania · US

Funding

Medical Research Council G1000729Medical Research Council MC_PC_19049Medical Research Council MC_U137961146Medical Research Council MC_UU_00016/11Medical Research Council MC_UU_00029/8Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1
6 · The paper itself

Abstract

Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753.

Indexed as

DancingLeukemia, Myeloid, AcuteAzacitidineBridged Bicyclo Compounds, HeterocyclicHumansIsocitrate DehydrogenaseMutationSulfonamidesAzacitidineBridged Bicyclo Compounds, HeterocyclicIDH1 protein, humanIsocitrate DehydrogenaseSulfonamidesvenetoclax

Identifiers

PMID35452083
OpenAlexW4224247142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.